Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer

Clinical trial NCT05633914 · UNKNOWN

Trial details

NCT number: NCT05633914
Sponsor: Hunan Cancer Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

HR+/HER2- Breast Cancer

Start date: 2023-02-07
Primary completion: 2024-12-01
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.